Divergent CNS-Peripheral Signaling Reflects Astrocyte Dysfunction and Contributes to Insulin Resistance in Early Aβ...

Area of Science:

• Neuroscience
• Metabolic Disorders
• Immunology

Background:

• Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) share features like insulin resistance and inflammation.
• The exact causes of brain insulin resistance in AD are not fully understood.
• Astrocytes' role in AD-related brain insulin resistance requires further clarification.

Purpose of the Study:

• To investigate the specific role of astrocytes in brain insulin resistance during early Alzheimer's disease.
• To differentiate CNS-specific metabolic impairments in AD from peripheral T2DM.

Main Methods:

• Focused on J20 mouse model during amyloid-β (Aβ) plaque deposition, excluding peripheral factors.
• Utilized transcriptomic profiling to analyze gene expression changes.
• Assessed astrocyte numbers, morphology, and cytokine levels (IL-6, IL-17) in the hippocampus and serum.

Main Results:

• Observed reduced astrocyte numbers and altered morphology with Aβ progression.
• Transcriptomic analysis revealed suppressed insulin signaling pathways and altered synaptic, glial, and metabolic gene expression.
• Found downregulation of SGK1 and upregulation of IRS2, differing from peripheral insulin resistance patterns.
• Detected contradictory IL-6 and IL-17 levels between hippocampus and serum, indicating immune dysregulation.

Conclusions:

• Astrocyte depletion and/or dysfunction are critical drivers of brain-specific insulin resistance in early AD.
• Downregulation of SGK1 and altered immune signaling contribute to AD pathogenesis.
• Metabolic dysfunction in AD exhibits CNS-specific characteristics distinct from T2DM.